James Kuo

Last updated

James Kuo is founder, CEO and Chairman of the Board of Salt Lake City-based BioMicro Systems, a company that makes research tools that control fluids by using hydrophilic (water-attracting) and hydrophobic (water-repelling) materials instead disruptive mechanical or electrical components. [1]

Early life and career

Kuo was born in Taiwan and came to the United States at the age of three. He earned an undergraduate degree at Haverford College in Haverford, Pa., a medical degree at University of Pennsylvania, and a Master of Business Administration from its Wharton School. [2]

Kuo launched his career by combining his medical degree with his MBA to become a guru in the high-stakes business of discovering and developing promising drug candidates.

At the age of 27, Kuo was already director of a $380 million fund at America's leading biotech venture capital firm. He helped launch Human Genome Sciences and Genetic Therapy Inc. Five years later he became CEO of Discovery Laboratories, an unfunded startup, and within six months raised $22 million through private placement. He then became Managing Director of Venture Analysis at HealthCare Ventures, a $378 million venture fund. In 2001 he became CEO of Microbiotix, Inc. Earlier in his career Kuo held senior business development positions at Pfizer, Genset Corporation and Myriad Genetics. Kuo also serves on the board of DOR BioPharma (AMEX: DOR), among other positions. [3]

In February 2010, Kuo was appointed as Chairman, CEO and President of Adeona Pharmaceuticals, Inc. [4]

Related Research Articles

<span class="mw-page-title-main">Columbia Business School</span> Business school of Columbia University

Columbia Business School (CBS) is the business school of Columbia University, a private research university in New York City. Established in 1916, Columbia Business School is one of six Ivy League business schools and is one of the oldest business schools in the world.

<span class="mw-page-title-main">Brook Byers</span>

Brook Byers is a senior partner at Kleiner Perkins Caufield & Byers and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.

Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.

Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, Genzyme and other companies.

Gary Lewis Crittenden is an American financial manager. He is an executive director of HGGC, and was previously CEO and chairman. He is also the former chairman of Citi Holdings. He was chairman of Citadel, Power Holdings, and iQor; lead independent director of Pluralsight; and has sbeen on the boards of Extra Space Storage, Staples Inc., Ryerson, Inc., TJX Companies, and Utah Capital Investment Corp. From 2000 to 2007, Crittenden was executive vice president and chief financial officer (CFO) of American Express, and from March 2007 to March 2009, he was the chief financial officer of Citigroup.

Randal J. Kirk is an American billionaire businessman and investor in pharmaceuticals and biotechnology. Kirk was the chairman and chief executive officer of Intrexon, a biotechnology company, until 2020. Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies. In addition to high-profile sales of New River Pharmaceuticals, and Clinical Data, Kirk founded investment firm Third Security, and has held board seats with biotech companies, such as Scios. As of May 2024, Forbes estimated his net worth at US$1.4 billion.

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Terry McGuire is a co-founder and general partner of Polaris Partners based in the Boston office. McGuire focuses on life sciences investments.

Christoph Westphal is an American biomedical businessman.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Richard B. Hollis</span> American businessman

Richard B. Hollis is an American businessman. He is the founder, chairman, and CEO of Holonis, Inc., a San Diego-based software company. Hollis had previously founded Hollis-Eden Pharmaceuticals, a San Diego-based pharmaceutical company, in 1994.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">David Lucchino</span>

David L. Lucchino is co-founder and chief executive officer of Frequency Therapeutics, a biotechnology company based in Lexington, MA.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.

References

  1. ↑ "James Kuo Founder, CEO and Chairman of the Board of BioMicro Systems | Top Asian American Professionals". Goldsea. Retrieved 2012-02-21.
  2. ↑ "San Diego Metropolitan - 40 Under 40 - September 2001". Sandiegometro.archives.whsites.net. Archived from the original on 2012-05-01. Retrieved 2012-02-21.
  3. ↑ Beers, Heather. "Articles". Utah Business. Archived from the original on 2012-09-14. Retrieved 2012-02-21.
  4. ↑ "Adeona Pharmaceuticals (AEN) Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President". FierceBiotech. Retrieved 2012-02-21.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.